Last C$0.34 CAD
Change Today -0.015 / -4.29%
Volume 23.2K
SDI On Other Exchanges
Symbol
Exchange
OTC US
Berlin
Toronto
As of 3:31 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

spectral diagnostics inc (SDI) Snapshot

Open
C$0.35
Previous Close
C$0.35
Day High
C$0.35
Day Low
C$0.34
52 Week High
11/12/13 - C$0.77
52 Week Low
03/19/14 - C$0.22
Market Cap
60.1M
Average Volume 10 Days
33.7K
EPS TTM
C$-0.09
Shares Outstanding
179.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRAL DIAGNOSTICS INC (SDI)

Related News

No related news articles were found.

spectral diagnostics inc (SDI) Related Businessweek News

No Related Businessweek News Found

spectral diagnostics inc (SDI) Details

Spectral Diagnostics Inc. develops and commercializes theranostic treatment for severe sepsis in North America. The company’s products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. It is also involved in the development, production, and marketing of recombinant cardiac proteins, antibodies, and calibrators for use in research and development, as well as in products manufactured by other diagnostic companies. The company was founded in 1991 and is headquartered in Toronto, Canada.

20 Employees
Last Reported Date: 03/27/14
Founded in 1991

spectral diagnostics inc (SDI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: C$424.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: C$265.6K
Vice President of Clinical Development
Total Annual Compensation: C$201.8K
Vice President of Sales and Marketing
Total Annual Compensation: C$117.8K
Compensation as of Fiscal Year 2013.

spectral diagnostics inc (SDI) Key Developments

Spectral Diagnostics Inc. Reports Un-Audited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Spectral Diagnostics Inc. reported un-audited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of CAD 778,000 compared to CAD 572,000 for the same period in the preceding year. The company reported a loss and comprehensive loss of CAD 2,451,000 or CAD 0.02 per basic and diluted common share compared to CAD 3,040,000 or CAD 0.02 per basic and diluted common share for the three months ended June 30, 2013. Operating loss was CAD 2,451,000 compared to CAD 3,056,000 reported in last year. For the six months revenues were CAD 1,622,000 compared to CAD 1,280,000 in the first half of 2013, Revenues were positively affected by the timing of certain customer orders and by the foreign exchange impact of a strengthening USD. Loss and comprehensive loss was CAD 5,626,000 or CAD 0.04 per basic and diluted common share compared to CAD 5,142,000 or CAD 0.04 per basic and diluted common share for the same six month period in the prior year. Operating loss was CAD 5,626,000 compared to CAD 5,175,000, net cash used in operating activities was CAD 5,774,000 compared to CAD 5,158,000 and property, plant and equipment expenditures was CAD 14,000 compared to CAD 236,000 reported in last year.

Spectral Diagnostics Inc. Reports Closing of Tranche 'A'

Spectral Diagnostics Inc. and Toray Industries Inc. reported the closing of Tranche 'A' of the previously announced non-brokered private placement for aggregate proceeds of $13.2 million.

Spectral Diagnostics Inc. Proposes Offering of Up to $18.2 Million

Spectral Diagnostics Inc. entered into agreements for a non-brokered private placement of up to $18.2 million. The corporation intends to use the net proceeds of the Proposed Offering to fund its EUPHRATES clinical development program for PMX, its lead theranostics product for the treatment of severe sepsis with septic shock and for working capital and general corporate purposes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SDI:CN C$0.34 CAD -0.015

SDI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SDI.
View Industry Companies
 

Industry Analysis

SDI

Industry Average

Valuation SDI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.5x
Price/Book 134.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRAL DIAGNOSTICS INC, please visit www.spectraldx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.